Home Accelerometry Did Not Confirm a Treatment-Specific Tremor Benefit in the Parkinson Trial
The trial’s home tremor measurements did not show a cannabinoid treatment advantage. Improvement within selected clinic tremor scores did not establish the same benefit across measurement methods.
The investigators used more than one approach
Clinic MDS-UPDRS tremor subscores were supplemented by an accelerometry-based assessment of rest tremor in clinic and at home. The latter measured features such as presence, amplitude and duration while participants performed specified movements with the opposite hand.
Within-group changes did not settle the controlled comparison
The active group improved on some clinic tremor subscores, while placebo showed improvement on others. The between-group comparisons did not establish a treatment effect. The in-home objective tremor measure likewise did not show an advantage of CBD/THC.
Measurement methods retain their own scope
A rating scale and an instrumented recording do not capture every aspect of tremor identically. Neither should be substituted silently for the other, and a favorable within-group subscore cannot override a negative controlled comparison. The short trial supplies evidence about this preparation under its protocol; it does not prove that every tremor in every person is unaffected. Reporting both measurement approaches avoids presenting a selective clinic change as independently confirmed objective efficacy.
Related analysis: the study’s broader findings and limitations.
